Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

AGM Notification

19 Nov 2024 07:00

RNS Number : 6600M
Beximco Pharmaceuticals Ltd
19 November 2024
 

19 November 2024

 

BEXIMCO PHARMACEUTICALS LIMITED

 

AGM Notification

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the forty-eighth Annual General Meeting of Shareholders (AGM) of Beximco Pharma will be held on Sunday, the 29th December, 2024 at 10.30 am Bangladesh time under the Virtual Platform through https://bxpharma.bdvirtualagm.com to transact the following business:

 

AGENDA

 

ORDINARY BUSINESS:

 

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30th June, 2024 together with reports of the Auditors and the Directors thereon.

2. To declare 40% cash dividend as recommended by the Board of Directors.

3. To elect Directors.

4. To approve the appointment of Managing Director.

5. To approve the re-appointment of Independent Director.

6. To appoint Statutory Auditors for the year 2024-25 and to fix their remuneration.

7. To appoint Corporate Governance Compliance Auditors for the year 2024-25 and to fix their remuneration.

 

SPECIAL BUSINESS:

 

To pass Special Resolutions to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" as per the provision of the Companies Act, 1994 (as amended in 2020) and to effect the change of the name in the relevant Clauses of the Memorandum and Articles of Association of the Company.

 

The draft of the Special Resolutions proposed to be passed is given below:

 

"Resolved that the name of the Company be changed from Beximco Pharmaceuticals Limited to Beximco Pharmaceuticals PLC and the new name of the Company be incorporated in the Memorandum and Articles of Association of the Company and an amended copy of the Memorandum and Articles of Association of the Company be and is hereby adopted and the same be filed with the Registrar of Joint Stock Companies, Dhaka, Bangladesh for record."

 

Dated: November 18, 2024

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

 

 

NOTES:

(1) The Shareholders whose names appear in the Share Register of the Company or in the Depository Register on the record date i.e. 25 November, 2024 will be entitled to receive the dividend and to attend the Annual General Meeting.

 

(2) A Member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Share Department of the Company at BEL Tower, Level-2, 19 Dhanmondi, Road No.1, Dhaka-1205, no later than 48 hours before the time fixed for the meeting.

 

(3) Annual Report for the year 2023-24 will be sent through e-mail address of the valued Shareholders and will be available in the Website of the Company at: www.beximcopharma.com.

 

(4) The valued Shareholders will join the Virtual AGM through the Link https://bxpharma.bdvirtualagm.com. The Shareholders will be able to submit their questions/comments and vote electronically 24 (Twenty-four) hours before commencement of the AGM and also during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as proof by visiting the said Link.

 

(5) We encourage the Shareholders to login into the system prior to the meeting. Please allow ample time to login and establish your connectivity. For any IT related guidance, Shareholders may contact vide email : monir@beximco.net or mazibur@beximco.net.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUWVORSKUAAAA
Date   Source Headline
5th Mar 20269:13 amRNSUpdate on Writ Petitions
28th Jan 20262:01 pmRNSOrder re Extension to Publish Financial Results
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
13th Nov 20254:00 pmRNSRequest of Extension to Publish Q1 Results
4th Nov 20257:00 amRNSChange of Name to Beximco Pharmaceuticals PLC.
27th Oct 20253:53 pmRNSRequest of Extension to Publish Financial Results
24th Oct 20257:00 amRNS-RAffordable treatment option for cystic fibrosis
15th Sep 20251:17 pmRNSFurther update on BSEC Order
21st May 20253:18 pmRNSUpdate on BSEC Order
28th Apr 20257:00 amRNSRequest of Extension to Publish Q3 Results
21st Mar 20253:51 pmRNSResponse to media reports and update on BSEC order
6th Mar 20257:00 amRNSUpdate on BSEC order
30th Jan 20252:59 pmRNSPayment of Cash Dividend
29th Jan 20257:01 amRNSBoard Changes
29th Jan 20257:00 amRNSHalf Year Results 2024-25
14th Jan 202511:24 amRNSBoard of Directors
30th Dec 20247:00 amRNSAnnual General Meeting Statement
19th Nov 20247:00 amRNSAGM Notification
14th Nov 20247:00 amRNSFinancial Results for the First Quarter
12th Nov 202410:00 amRNSRestoration - Beximco Pharmaceuticals Limited
12th Nov 202410:00 amRNSUpdate on Interim Order Supreme Court decision
11th Nov 202411:01 amRNSFurther re the Temporary Suspension of Trading
11th Nov 20247:30 amRNSSuspension - Beximco Pharmaceuticals Limited
7th Nov 20247:00 amRNSResults for the year ended 30 June 2024
29th Oct 20247:00 amRNSNotification of Preliminary Results and AGM
28th Oct 20242:35 pmRNSUpdate on Writ Petition and Interim Order
2nd Oct 20247:00 amRNSUpdate on Writ Petition and Interim Order
30th Sep 20247:06 amRNSClarification on Writ Petition
6th Sep 20242:17 pmRNSUpdate regarding Vice-Chairman, Salman Rahman
3rd Sep 20241:45 pmRNSCorrection and Clarification of Press Commentary
15th Aug 20247:00 amRNSStatement regarding Vice-Chairman, Salman Rahman
13th Aug 20247:00 amRNSStatement on political and business situation
30th Apr 20247:00 amRNSQ3 Financial Results
4th Mar 20247:00 amRNSAppointment of Managing Director
30th Jan 20247:00 amRNSHalf Year Results 2023-24
25th Jan 20249:53 amRNSPayment of Cash Dividend
11th Jan 202411:44 amRNSBoard Change
28th Dec 20239:40 amRNSAGM Statement
6th Nov 202312:17 pmRNSNotice of AGM
6th Nov 20237:00 amRNSFinancial Results for the First Quarter
1st Nov 20237:00 amRNSResults for the year ended 30 June 2023
20th Oct 20237:00 amRNSNotification of Preliminary Results and AGM
11th Sep 202310:17 amRNSClarification on Press Report
31st Aug 20233:51 pmRNSRe-appointment of Independent Director
2nd May 20237:00 amRNSQ3 Financial Results
11th Apr 20233:59 pmRNSHoldings in Company
31st Mar 202311:03 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.